Zacks Rank #5 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 09, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Friday
Bio-Rad Reports First-Quarter 2014 Financial Results
Marketwire - Wed May 07, 5:20AM CDT
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.
Bio-Rad Named One of the '2014 Best Places to Work in the Bay Area'
Marketwire - Mon Apr 28, 3:06PM CDT
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.
Bio-Rad to Report First-Quarter 2014 Financial Results Tuesday, May 6, 2014
Marketwire - Wed Apr 16, 11:33AM CDT
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.
Bio-Rad Buys GnuBio - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 5:00PM CDT
GnuBIO is a privately-held life sciences company that has developed a fast and fully integrated droplet-based DNA sequencing platform.
Bio-Rad Acquires GnuBIO and DNA Sequencing Technology
Marketwire - Thu Apr 10, 7:01PM CDT
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.
Bio-Rad Reports Fourth-Quarter and Full-Year 2013 Financial Results
Marketwire - Thu Feb 27, 3:15PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.
Arik Air Expands Into West African Countries
All Africa Global Media - Wed Feb 26, 6:41AM CST
Arik Air has extended two of its existing routes as the airline continues its expansion programme for the regional West African services.
IIROC Trade Resumption - RMX
CNW Group - Thu Feb 20, 7:17AM CST
Trading resumes in:
Can Investors Gain from the New Age in Medical Testing?
Bob Chandler, The Motley Fool - Motley Fool - Thu Feb 06, 5:30PM CST
We might be entering a new age in medical testing. Molecular-level diagnostics, or tests based on the role genes play in human diseases, looks to provide earlier detection and more effective treatments for the most deadly conditions. Can investors...
Bio-Rad to Report Fourth-Quarter and Full-Year 2013 Financial Results Thursday, February 27, 2014
Marketwire - Mon Jan 27, 6:44PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.
4 Stocks Rising on Unusual Volume
at The Street - Thu Jan 23, 6:00AM CST
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
NYSE stocks posting largest volume increases
AP - Wed Jan 22, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on New York Stock Exchange at the close of trading:
Zacks #5 Rank Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 03, 8:30AM CST
Here are 5 stocks added to the Zacks #5 Rank ("strong sell"
Zacks #5 Rank Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 31, 8:30AM CST
Here are 5 stocks added to the Zacks #5 Rank ("strong sell"
New Products, Price Movements, and Leadership Appointments - Research Report on Waters, Cognex, Fluidigm, Cepheid, and Bio-Rad
PR Newswire - Mon Dec 23, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Waters Corp. (NYSE: WAT), Cognex Corporation (NASDAQ: CGNX), Fluidigm Corporation (NASDAQ: FLDM), Cepheid (NASDAQ: CPHD), and Bio-Rad Laboratories, Inc. (NYSE: BIO). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
CareFusion Unveils New Technologies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 20, 12:50PM CST
CareFusion unveiled a number of technologies that will lead to better medication management with improved safety, efficiency and cost of intravenous (IV) medications.
athenahealth Collaborates with Merge - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 19, 3:15PM CST
ATHN will use MRGE's iConnect Network in its cloud-based platform that will help its clients have real time access to view exam results, diagnostic images and other critical information within the athenaClinicals EHR workflow
Cerner Approves New Share Repurchase - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 18, 1:30PM CST
Under the previous share repurchase program, authorized in December 2012, CERN repurchased 3.6 million shares for $170.0 million.